Nanotechnology based advanced therapeutic strategies for targeting interleukins in chronic respiratory diseases

Md Sadique Hussain, Parvarish Sharma, Daljeet Singh Dhanjal, Navneet Khurana, Manish Vyas, Neha Sharma, Meenu Mehta, Murtaza M. Tambuwala, Saurabh Satija, Sukhwinder Singh Sohal, Brian.g.g. Oliver, Hari S. Sharma

Research output: Contribution to journalArticlepeer-review

4 Citations (Scopus)


Both communicable and non-communicable chronic respiratory conditions have accorded for
suffering of millions of people of all ages and stated to be leading cause of death, morbidity,
economic and social pressures, and disability-adjusted life-years (DALYs) worldwide. These
illnesses impair patient’s health and negatively impacts families and society, particularly in
low and middle-income countries. Chronic respiratory diseases (CRDs) affect different
organs of respiratory system, involving airways, parenchyma, and pulmonary vasculature. As
the number of respiratory diseases are exponentially escalating but still the stakeholders are
not paying attention towards its serious complications. Currently, the treatment being used
primarily focusses only on alleviating symptoms of these illness rather delivering the
therapeutic agent at target site for optimal care and/or prevention. Lately, extensive research
is being conducted on airways and systemic inflammation, oxidative stress, airway, or
parenchymal rehabilitation. From which macrophages, neutrophils, and T cells, as well as
structural cells as fibroblasts, epithelial, endothelial, and smooth muscle cells have been
found to be active participants that are involved in these chronic respiratory diseases. The
pathogenesis of all these chronic respiratory diseases gets caused differently via mediators
and proteins, including cytokines, chemokines, growth factors and oxidants. Presently, the
target of prescription therapies is to reduce the inflammation of airways and relieve the
airway contraction. In all studies, cytokines have been found to play an imperative role in
fostering chronic airway inflammation and remodelling. Owing to the limitations of
conventional treatments, the current review aims to summarize the current knowledge about
the chronic respiratory disease and discuss further about the various conventional methods
that can be used for treating this ailment. Additionally, it also highlights and discusses about
the advanced drug delivery system that are being used for targeting the interleukins for the
treatment of CRDs
Original languageEnglish
Number of pages46
JournalChemico-Biological Interactions
Publication statusPublished - 8 Sep 2021


Dive into the research topics of 'Nanotechnology based advanced therapeutic strategies for targeting interleukins in chronic respiratory diseases'. Together they form a unique fingerprint.

Cite this